These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38289534)

  • 1. Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.
    Bajrami A; Tamanti A; Peloso A; Ziccardi S; Guandalini M; Calderone M; Castellaro M; Pizzini FB; Montemezzi S; Marastoni D; Calabrese M
    J Neurol; 2024 May; 271(5):2149-2158. PubMed ID: 38289534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis.
    Crescenzo F; Marastoni D; Zuco C; Pitteri M; Magliozzi R; Monaco S; Calabrese M
    Mult Scler Relat Disord; 2019 Jan; 27():305-311. PubMed ID: 30453199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
    J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of fingolimod on focal and diffuse grey matter damage in active MS patients.
    Bajrami A; Pitteri M; Castellaro M; Pizzini F; Romualdi C; Montemezzi S; Monaco S; Calabrese M
    J Neurol; 2018 Sep; 265(9):2154-2161. PubMed ID: 29938336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cortical and Subcortical Morphometric and Iron Changes in Relapsing-Remitting Multiple Sclerosis and Their Association with White Matter T2 Lesion Load : A 3-Tesla Magnetic Resonance Imaging Study.
    Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
    Clin Neuroradiol; 2019 Mar; 29(1):51-64. PubMed ID: 29299614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
    Gaetano L; Häring DA; Radue EW; Mueller-Lenke N; Thakur A; Tomic D; Kappos L; Sprenger T
    Neurology; 2018 Apr; 90(15):e1324-e1332. PubMed ID: 29540589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
    J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis.
    Zivadinov R; Ramanathan M; Hagemeier J; Bergsland N; Ramasamy DP; Durfee J; Kolb C; Weinstock-Guttman B
    Mult Scler Relat Disord; 2019 Nov; 36():101388. PubMed ID: 31525628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
    Eijlers AJC; van Geest Q; Dekker I; Steenwijk MD; Meijer KA; Hulst HE; Barkhof F; Uitdehaag BMJ; Schoonheim MM; Geurts JJG
    Brain; 2018 Sep; 141(9):2605-2618. PubMed ID: 30169585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focal cortical thinning in patients with stable relapsing-remitting multiple sclerosis: cross-sectional-based novel estimation of gray matter kinetics.
    Orbach L; Menascu S; Hoffmann C; Miron S; Achiron A
    Neuroradiology; 2018 Feb; 60(2):179-187. PubMed ID: 29285552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
    Hauser SL; Kappos L; Arnold DL; Bar-Or A; Brochet B; Naismith RT; Traboulsee A; Wolinsky JS; Belachew S; Koendgen H; Levesque V; Manfrini M; Model F; Hubeaux S; Mehta L; Montalban X
    Neurology; 2020 Sep; 95(13):e1854-e1867. PubMed ID: 32690791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gray matter integrity predicts white matter network reorganization in multiple sclerosis.
    Radetz A; Koirala N; Krämer J; Johnen A; Fleischer V; Gonzalez-Escamilla G; Cerina M; Muthuraman M; Meuth SG; Groppa S
    Hum Brain Mapp; 2020 Mar; 41(4):917-927. PubMed ID: 32026599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
    Arnold DL; Sprenger T; Bar-Or A; Wolinsky JS; Kappos L; Kolind S; Bonati U; Magon S; van Beek J; Koendgen H; Bortolami O; Bernasconi C; Gaetano L; Traboulsee A
    Mult Scler; 2022 Oct; 28(12):1927-1936. PubMed ID: 35672926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two years' effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis.
    Marastoni D; Crescenzo F; Pisani AI; Zuco C; Schiavi G; Benedetti G; Ricciardi GK; Montemezzi S; Pizzini FB; Tamanti A; Calabrese M
    Mult Scler; 2022 Nov; 28(13):2090-2098. PubMed ID: 35765211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of cortical grey matter thickness reduction in multiple sclerosis.
    Fujimori J; Fujihara K; Wattjes M; Nakashima I
    Brain Behav; 2021 Apr; 11(4):e02050. PubMed ID: 33506628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal Fluid-In Gradient of Cortical and Deep Gray Matter Damage in Multiple Sclerosis.
    Rubin M; Pagani E; Preziosa P; Meani A; Storelli L; Margoni M; Filippi M; Rocca MA
    Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200271. PubMed ID: 38896808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial.
    Nakamura K; Sun Z; Hara-Cleaver C; Bodhinathan K; Avila RL
    Mult Scler; 2024 May; 30(6):687-695. PubMed ID: 38469809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern of gray matter volumes related to retinal thickness and its association with cognitive function in relapsing-remitting MS.
    Stellmann JP; Cetin H; Young KL; Hodecker S; Pöttgen J; Bittersohl D; Hassenstein A; Oberwahrenbrock T; Heesen C; Siemonsen S
    Brain Behav; 2017 Feb; 7(2):e00614. PubMed ID: 28239524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Staging of cortical and deep grey matter functional connectivity changes in multiple sclerosis.
    Meijer KA; Eijlers AJC; Geurts JJG; Schoonheim MM
    J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):205-210. PubMed ID: 28986469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis.
    Calabrese M; Rinaldi F; Grossi P; Mattisi I; Bernardi V; Favaretto A; Perini P; Gallo P
    Mult Scler; 2010 Oct; 16(10):1220-8. PubMed ID: 20670981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.